公开(公告)号：US20140370502A1

公开(公告)日：2014-12-18

申请号：US14343483

申请日：2012-09-10

申请人： Ed Brennan ,  Conan Li ,  Alexander Belenky

发明人： Ed Brennan ,  Conan Li ,  Alexander Belenky

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N33/54386 ,  G01N33/6887 ,  G01N2333/4712 ,  G01N2800/324 ,  G01N2800/325

摘要： The present invention provides methods and devices for detecting the presence of two or more threshold levels of an analyte, including markers of myocardial damage such as cardiac troponins, in a sample. In various embodiments, the invention provides convenient point-of-care tests for determining the condition of a patient, so as to guide cost effective health care.

摘要翻译： 本发明提供了用于检测样品中两种或多种阈值水平的分析物（包括心肌损伤标记物如心肌蛋白沉积物）的存在的方法和装置。 在各种实施例中，本发明提供了用于确定患者状况的便利的护理点测试，以便指导成本有效的保健。

公开(公告)号：US08003385B2

公开(公告)日：2011-08-23

申请号：US12707563

申请日：2010-02-17

申请人： Selva Sukumar ,  Mohey Eldin M. El Shikh ,  John G. Tew ,  Guzman Sanchez-Schmitz ,  Donald Drake, III ,  Luis Mosquera ,  Conan Li ,  Anatoly M. Kachurin ,  Russell Higbee ,  Heather Fahlenkamp ,  Eric Mishkin ,  William L. Warren

发明人： Selva Sukumar ,  Mohey Eldin M. El Shikh ,  John G. Tew ,  Guzman Sanchez-Schmitz ,  Donald Drake, III ,  Luis Mosquera ,  Conan Li ,  Anatoly M. Kachurin ,  Russell Higbee ,  Heather Fahlenkamp ,  Eric Mishkin ,  William L. Warren

IPC分类号： C12N5/06 ,  C12N5/02

CPC分类号： C07K16/44 ,  C12N5/0639 ,  C12N5/0651 ,  C12N5/0697 ,  C12N2501/052 ,  C12N2501/21 ,  C12N2501/2304 ,  C12N2502/11 ,  C12N2502/1107 ,  C12N2502/1114 ,  C12N2502/1121 ,  C12N2502/1192 ,  C12N2502/28 ,  C12N2503/04 ,  C12N2533/50 ,  C12N2533/54 ,  C12N2533/92 ,  C12N2535/10 ,  G01N33/5047 ,  G01N33/5076 ,  G01N33/5088

摘要： The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

公开(公告)号：US08247226B2

公开(公告)日：2012-08-21

申请号：US13167115

申请日：2011-06-23

申请人： Selva Sukumar ,  Mohey Eldin M. El Shikh ,  John G. Tew ,  Guzman Sanchez-Schmitz ,  Donald Drake, III ,  Luis Mosquera ,  Conan Li ,  Anatoly M. Kachurin ,  Russell Higbee ,  Heather Fahlenkamp ,  Eric Mishkin ,  William L. Warren

发明人： Selva Sukumar ,  Mohey Eldin M. El Shikh ,  John G. Tew ,  Guzman Sanchez-Schmitz ,  Donald Drake, III ,  Luis Mosquera ,  Conan Li ,  Anatoly M. Kachurin ,  Russell Higbee ,  Heather Fahlenkamp ,  Eric Mishkin ,  William L. Warren

IPC分类号： C12N5/00 ,  C12N5/02

CPC分类号： C07K16/44 ,  C12N5/0639 ,  C12N5/0651 ,  C12N5/0697 ,  C12N2501/052 ,  C12N2501/21 ,  C12N2501/2304 ,  C12N2502/11 ,  C12N2502/1107 ,  C12N2502/1114 ,  C12N2502/1121 ,  C12N2502/1192 ,  C12N2502/28 ,  C12N2503/04 ,  C12N2533/50 ,  C12N2533/54 ,  C12N2533/92 ,  C12N2535/10 ,  G01N33/5047 ,  G01N33/5076 ,  G01N33/5088

摘要： The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

摘要翻译： 本发明将生发中心（GC）纳入三维（3D）工程组织构建体（ETC）中。 在一个实施方案中，我们已经将GC并入人造免疫系统（AIS）的设计中，以检查对疫苗和其他化合物的免疫应答。 体外GC的开发为AIS增加了功能，因为它能够在不使用人类受试者的情况下产生准确和可重复的人B淋巴细胞的体外人体液反应。 本发明还允许评估例如疫苗，过敏原和免疫原，以及对给定抗原特异性的人B细胞的活化，然后可以将其用于产生人抗体。 在本发明的一个实施方案中，通过将FDC和其他免疫细胞放置在3D ETC中来增强体外GC的功能; FDC在更长时间内看起来更有效（抗体产生持续长达约14天。

公开(公告)号：US08669105B2

公开(公告)日：2014-03-11

申请号：US13167131

申请日：2011-06-23

申请人： Selva Sukumar ,  Mohey Eldin M. El Shikh ,  John G. Tew ,  Guzman Sanchez-Schmitz ,  Donald Drake, III ,  Luis Mosquera ,  Conan Li ,  Anatoly M. Kachurin ,  Russell Higbee ,  Heather Fahlenkamp ,  Eric Mishkin ,  William L. Warren

发明人： Selva Sukumar ,  Mohey Eldin M. El Shikh ,  John G. Tew ,  Guzman Sanchez-Schmitz ,  Donald Drake, III ,  Luis Mosquera ,  Conan Li ,  Anatoly M. Kachurin ,  Russell Higbee ,  Heather Fahlenkamp ,  Eric Mishkin ,  William L. Warren

IPC分类号： C12N5/00 ,  C12N5/02

CPC分类号： C07K16/44 ,  C12N5/0639 ,  C12N5/0651 ,  C12N5/0697 ,  C12N2501/052 ,  C12N2501/21 ,  C12N2501/2304 ,  C12N2502/11 ,  C12N2502/1107 ,  C12N2502/1114 ,  C12N2502/1121 ,  C12N2502/1192 ,  C12N2502/28 ,  C12N2503/04 ,  C12N2533/50 ,  C12N2533/54 ,  C12N2533/92 ,  C12N2535/10 ,  G01N33/5047 ,  G01N33/5076 ,  G01N33/5088

摘要： The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

摘要翻译： 本发明将生发中心（GC）纳入三维（3D）工程组织构建体（ETC）中。 在一个实施方案中，我们已经将GC并入人造免疫系统（AIS）的设计中，以检查对疫苗和其他化合物的免疫应答。 体外GC的开发为AIS增加了功能，因为它能够在不使用人类受试者的情况下产生准确和可重复的人B淋巴细胞的体外人体液反应。 本发明还允许评估例如疫苗，过敏原和免疫原，以及对给定抗原特异性的人B细胞的活化，然后可以将其用于产生人抗体。 在本发明的一个实施方案中，通过将FDC和其他免疫细胞放置在3D ETC中来增强体外GC的功能; FDC在更长时间内看起来更有效（抗体产生持续长达约14天。

公开(公告)号：US08003387B2

公开(公告)日：2011-08-23

申请号：US11642938

申请日：2006-12-21

申请人： Selva Sukumar ,  Mohey Eldin M. El Shikh ,  John G. Tew ,  Guzman Sanchez-Schmitz ,  Donald Drake, III ,  Luis Mosquera ,  Eric Mishkin ,  Anatoly M. Kachurin ,  Russell Higbee ,  Conan Li ,  William L. Warren ,  Heather Fahlenkamp

发明人： Selva Sukumar ,  Mohey Eldin M. El Shikh ,  John G. Tew ,  Guzman Sanchez-Schmitz ,  Donald Drake, III ,  Luis Mosquera ,  Eric Mishkin ,  Anatoly M. Kachurin ,  Russell Higbee ,  Conan Li ,  William L. Warren ,  Heather Fahlenkamp

IPC分类号： C12N5/08 ,  C12N5/00 ,  C12N5/02

CPC分类号： C07K16/44 ,  C12N5/0639 ,  C12N5/0651 ,  C12N5/0697 ,  C12N2501/052 ,  C12N2501/21 ,  C12N2501/2304 ,  C12N2502/11 ,  C12N2502/1107 ,  C12N2502/1114 ,  C12N2502/1121 ,  C12N2502/1192 ,  C12N2502/28 ,  C12N2503/04 ,  C12N2533/50 ,  C12N2533/54 ,  C12N2533/92 ,  C12N2535/10 ,  G01N33/5047 ,  G01N33/5076 ,  G01N33/5088

摘要： The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

摘要翻译： 本发明将生发中心（GC）纳入三维（3D）工程组织构建体（ETC）中。 在一个实施方案中，我们已经将GC并入人造免疫系统（AIS）的设计中，以检查对疫苗和其他化合物的免疫应答。 体外GC的开发为AIS增加了功能，因为它能够在不使用人类受试者的情况下产生准确和可重复的人B淋巴细胞的体外人体液反应。 本发明还允许评估例如疫苗，过敏原和免疫原，以及对给定抗原特异性的人B细胞的活化，然后可以将其用于产生人抗体。 在本发明的一个实施方案中，通过将FDC和其他免疫细胞放置在3D ETC中来增强体外GC的功能; FDC在更长时间内看起来更有效（抗体产生持续长达约14天。

公开(公告)号：US08722402B2

公开(公告)日：2014-05-13

申请号：US13608579

申请日：2012-09-10

申请人： William L Warren ,  Heather Fahlenkamp ,  Russell Higbee ,  Anatoly Kachurin ,  Conan Li ,  Mike Nguyen ,  Robert Parkhill ,  Guzman Sanchez-Schmitz ,  Darrell J. Irvine ,  Gwendalyn J. Randolph ,  Nir Harcohen ,  Bruce Torbett

发明人： William L Warren ,  Heather Fahlenkamp ,  Russell Higbee ,  Anatoly Kachurin ,  Conan Li ,  Mike Nguyen ,  Robert Parkhill ,  Guzman Sanchez-Schmitz ,  Darrell J. Irvine ,  Gwendalyn J. Randolph ,  Nir Harcohen ,  Bruce Torbett

IPC分类号： C12N5/08 ,  C12N5/00 ,  C12N5/02

CPC分类号： G01N33/5008 ,  C12N5/0697 ,  C12N5/0698 ,  C12N2501/21 ,  C12N2502/094 ,  C12N2502/11 ,  C12N2502/1107 ,  C12N2502/1114 ,  C12N2502/1121 ,  C12N2502/1157 ,  C12N2502/1192 ,  C12N2502/1323 ,  C12N2502/28 ,  C12N2503/04 ,  C12N2513/00 ,  C12N2531/00 ,  C12N2533/50 ,  C12N2533/54 ,  C12N2535/10 ,  G01N33/5088 ,  G01N2500/10

摘要： The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

摘要翻译： 本发明涉及构建综合人造免疫系统的方法，其包括适当的体外细胞和组织构建体或其等同物以模拟与哺乳动物中的疫苗相互作用的正常组织。 人工免疫系统可用于测试疫苗候选物在体外的功效，因此可用于加速疫苗开发和测试与免疫系统的药物和化学相互作用。

公开(公告)号：US07855074B2

公开(公告)日：2010-12-21

申请号：US11116234

申请日：2005-04-28

申请人： William L. Warren ,  Heather Fahlenkamp ,  Russell Higbee ,  Anatoly Kachurin ,  Conan Li ,  Mike Nguyen ,  Robert Parkhill ,  Guzman Sanchez-Schmitz ,  Darrell J. Irvine ,  Gwendalyn J. Randolph ,  Nir Hacohen ,  Bruce Torbett

发明人： William L. Warren ,  Heather Fahlenkamp ,  Russell Higbee ,  Anatoly Kachurin ,  Conan Li ,  Mike Nguyen ,  Robert Parkhill ,  Guzman Sanchez-Schmitz ,  Darrell J. Irvine ,  Gwendalyn J. Randolph ,  Nir Hacohen ,  Bruce Torbett

IPC分类号： C12N5/08

CPC分类号： G01N33/5008 ,  C12N5/0697 ,  C12N5/0698 ,  C12N2501/21 ,  C12N2502/094 ,  C12N2502/11 ,  C12N2502/1107 ,  C12N2502/1114 ,  C12N2502/1121 ,  C12N2502/1157 ,  C12N2502/1192 ,  C12N2502/1323 ,  C12N2502/28 ,  C12N2503/04 ,  C12N2513/00 ,  C12N2531/00 ,  C12N2533/50 ,  C12N2533/54 ,  C12N2535/10 ,  G01N33/5088 ,  G01N2500/10

摘要： The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

摘要翻译： 本发明涉及构建综合人造免疫系统的方法，其包括适当的体外细胞和组织构建体或其等同物以模拟与哺乳动物中的疫苗相互作用的正常组织。 人工免疫系统可用于测试疫苗候选物在体外的功效，因此可用于加速疫苗开发和测试与免疫系统的药物和化学相互作用。

公开(公告)号：US08288159B2

公开(公告)日：2012-10-16

申请号：US12725698

申请日：2010-03-17

申请人： William L Warren ,  Heather Fahlenkamp ,  Russell Higbee ,  Anatoly Kachurin ,  Conan Li ,  Mike Nguyen ,  Robert Parkhill ,  Guzman Sanchez-Schmitz ,  Darrell J. Irvine ,  Gwendalyn J. Randolph ,  Nir Harcohen ,  Bruce Torbett

发明人： William L Warren ,  Heather Fahlenkamp ,  Russell Higbee ,  Anatoly Kachurin ,  Conan Li ,  Mike Nguyen ,  Robert Parkhill ,  Guzman Sanchez-Schmitz ,  Darrell J. Irvine ,  Gwendalyn J. Randolph ,  Nir Harcohen ,  Bruce Torbett

IPC分类号： C12N5/06 ,  C12N5/02

CPC分类号： G01N33/5008 ,  C12N5/0697 ,  C12N5/0698 ,  C12N2501/21 ,  C12N2502/094 ,  C12N2502/11 ,  C12N2502/1107 ,  C12N2502/1114 ,  C12N2502/1121 ,  C12N2502/1157 ,  C12N2502/1192 ,  C12N2502/1323 ,  C12N2502/28 ,  C12N2503/04 ,  C12N2513/00 ,  C12N2531/00 ,  C12N2533/50 ,  C12N2533/54 ,  C12N2535/10 ,  G01N33/5088 ,  G01N2500/10

摘要： The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

摘要翻译： 本发明涉及构建综合人造免疫系统的方法，其包括适当的体外细胞和组织构建体或其等同物以模拟与哺乳动物中的疫苗相互作用的正常组织。 人工免疫系统可用于测试疫苗候选物在体外的功效，因此可用于加速疫苗开发和测试与免疫系统的药物和化学相互作用。

公开(公告)号：US20110171689A1

公开(公告)日：2011-07-14

申请号：US12725698

申请日：2010-03-17

申请人： William L. Warren ,  Heather Fahlenkamp ,  Russell Higbee ,  Anatoly Kachurin ,  Conan Li ,  Mike Nguyen ,  Robert Parkhill ,  Guzman Sanchez-Schmitz ,  Darrell J. Irvine ,  Gwendalyn J. Randolph ,  Nir Hacohen ,  Bruce Torbett

发明人： William L. Warren ,  Heather Fahlenkamp ,  Russell Higbee ,  Anatoly Kachurin ,  Conan Li ,  Mike Nguyen ,  Robert Parkhill ,  Guzman Sanchez-Schmitz ,  Darrell J. Irvine ,  Gwendalyn J. Randolph ,  Nir Hacohen ,  Bruce Torbett

IPC分类号： C12P21/00

CPC分类号： G01N33/5008 ,  C12N5/0697 ,  C12N5/0698 ,  C12N2501/21 ,  C12N2502/094 ,  C12N2502/11 ,  C12N2502/1107 ,  C12N2502/1114 ,  C12N2502/1121 ,  C12N2502/1157 ,  C12N2502/1192 ,  C12N2502/1323 ,  C12N2502/28 ,  C12N2503/04 ,  C12N2513/00 ,  C12N2531/00 ,  C12N2533/50 ,  C12N2533/54 ,  C12N2535/10 ,  G01N33/5088 ,  G01N2500/10

摘要： The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

摘要翻译： 本发明涉及构建综合人造免疫系统的方法，其包括适当的体外细胞和组织构建体或其等同物以模拟与哺乳动物中的疫苗相互作用的正常组织。 人工免疫系统可用于测试疫苗候选物在体外的功效，因此可用于加速疫苗开发和测试与免疫系统的药物和化学相互作用。

公开(公告)号：US20070218054A1

公开(公告)日：2007-09-20

申请号：US11642938

申请日：2006-12-21

申请人： Selva Sukumar ,  Mohey Eldin El Shikh ,  John Tew ,  Guzman Sanchez-Schmitz ,  Donald Drake ,  Luis Mosquera ,  Eric Mishkin ,  Anatoly Kachurin ,  Russell Higbee ,  Conan Li ,  William Warren ,  Heather Fahlenkamp

发明人： Selva Sukumar ,  Mohey Eldin El Shikh ,  John Tew ,  Guzman Sanchez-Schmitz ,  Donald Drake ,  Luis Mosquera ,  Eric Mishkin ,  Anatoly Kachurin ,  Russell Higbee ,  Conan Li ,  William Warren ,  Heather Fahlenkamp

IPC分类号： A61K39/395 ,  G01N33/567 ,  C12P21/04 ,  C12N5/08

CPC分类号： C07K16/44 ,  C12N5/0639 ,  C12N5/0651 ,  C12N5/0697 ,  C12N2501/052 ,  C12N2501/21 ,  C12N2501/2304 ,  C12N2502/11 ,  C12N2502/1107 ,  C12N2502/1114 ,  C12N2502/1121 ,  C12N2502/1192 ,  C12N2502/28 ,  C12N2503/04 ,  C12N2533/50 ,  C12N2533/54 ,  C12N2533/92 ,  C12N2535/10 ,  G01N33/5047 ,  G01N33/5076 ,  G01N33/5088

摘要： The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

摘要翻译： 本发明将生发中心（GC）纳入三维（3D）工程组织构建体（ETC）中。 在一个实施方案中，我们已经将GC并入人造免疫系统（AIS）的设计中，以检查对疫苗和其他化合物的免疫应答。 体外GC的开发为AIS增加了功能，因为它能够在不使用人类受试者的情况下产生准确和可重复的人B淋巴细胞的体外人体液反应。 本发明还允许评估例如疫苗，过敏原和免疫原，以及对给定抗原特异性的人B细胞的活化，然后可以将其用于产生人抗体。 在本发明的一个实施方案中，通过将FDC和其他免疫细胞放置在3D ETC中来增强体外GC的功能; FDC在更长时间内看起来更有效（抗体产生持续长达约14天。